Last reviewed · How we verify
Drug-induced mucositis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Kepivance | PALIFERMIN | Biovitrum Ab | Mucocutaneous Epithelial Cell Growth Factor [EPC] | Fibroblast growth factor receptor 2 | 2004-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Biovitrum Ab · 1 drug in Drug-induced mucositis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Drug-induced mucositis:
- Drug-induced mucositis treatment updates — RSS
- Drug-induced mucositis treatment updates — Atom
- Drug-induced mucositis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Drug-induced mucositis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/drug-induced-mucositis. Accessed 2026-06-10.
Related
- Drug-induced mucositis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing